Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pERK signaling study in RASopathy-associated lymphatic disease
NL-OMON58447Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2026
- Countries
- 1
01
Overview
Open-label trial in RASopathies, Noonan syndrome, central conducting lymphatic anomaly (CCLA) and 2 more (2 cohorts), sponsored by Radboud University Medical Center. Primary endpoint: Change in pERK1/2 levels corrected for total ERK. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
RASopathiesNoonan syndromecentral conducting lymphatic anomaly (CCLA)lymphangiomacentral lymphatic disorder (CLD)
Beyond the preview
Go deeper on NL-OMON58447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58447.